A Tolerance and Pharmacokinetic Study of Trodusquemine in Healthy Volunteers
Completed · Phase 1
Conditions studied: Obesity
In brief
The purpose of this study is to evaluate the safety and tolerance of single intravenous (through a vein) doses of trodusquemine. Different amounts of trodusquemine will be given to each volunteer group throughout the study. Another purpose is to evaluate the pharmacokinetics (PK - the study of the way the drug enters and leaves the blood and tissues over time) of trodusquemine. Finally, this study will also determine whether trodusquemine has any effect on appetite, mood or behavior, and selective biomarkers (substances in your blood that may change in response to the study drug).
Key facts
- Study ID
- NCT00509132
- Run by
- Genaera Corporation
- People needed
- 42
- Starts
- 2007-05-01
- Expected to finish
- 2007-10-01
- Last updated by the study team
- 2008-01-09
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- male or female subjects, between 18 and 55 years old (inclusive);
- body mass index (BMI) of 27-40 kg/m2;
You may not qualify if…
- likely allergy or sensitivity to any components of Trodusquemine for Injection based on known allergies to drugs of the same class, or which, in the opinion of the Principal Investigator, suggests an increased potential for an adverse hypersensitivity to trodusquemine HCl;
- any subject with a history of allergy (rash, hives, breathing difficulty, etc.) to any medications, either prescription or nonprescription, including dietary supplements or herbal medications;
- any subject with a history of severe allergy or bronchial asthma;
Where it is running
- Quintiles, Inc. — Overland Park, Kansas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.